– The offer is considered to be able to take effect soon in the municipalities and as soon as it is practically possible in the hospitals. The National Institute of Public Health further recommends that the group with severely weakened immune systems be defined as clearly as possible, writes NIPH in a response to an assignment from the Ministry of Health.
FHI further writes that at present it is considered that there is no basis for repeated vaccination of other groups, such as for example the oldest part of the population.
– But this can change in the future, writes FHI.
They point out that it is still uncertain how long the protection against covid-19 is after vaccination with the mRNA vaccines (Pfizer and Moderna). They believe the duration depends on the vaccinated person’s age and state of health, as well as how the virus and the epidemic develop further.
Lower immune response
Adult immunosuppressed patients have an increased risk of becoming seriously ill with covid-19, and in addition, several studies have shown that highly immunosuppressed patients have a lower immune response after two vaccine doses than immunocompromised individuals.
– Experiences from other vaccines have shown that some patient groups with severely weakened immune systems achieve a higher degree of protection after one or more extra doses, while some patient groups do not achieve protection even after revaccination, FHI writes.
Denmark also decided earlier this month that these patient groups should receive a third dose. An active research project is underway at Ahus where patients taking active immunosuppressive medication receive a third dose of vaccine, called Nor-Vac.
Cancer patients and organ transplant recipients
FHI recommends that the following patient groups be offered a third dose of vaccine:
* Organ transplantation, bone marrow transplantation in the last 2 years, or an ongoing graft versus cough disease that requires immunosuppression after assessment by a treating specialist.
* Severe and moderate primary immune deficiency
* Cancer patients with active or recently undergone immunosuppressive therapy
* Active dialysis treatment and patients with chronic renal failure stage 5
* Advanced or untreated HIV
* Ongoing significant immunosuppressive treatment for other reasons where indication has been assessed by the specialist health service.
* Patients who by a responsible medical specialist consider to have a severely impaired immune system and who are not part of one of the groups above. Age alone is not currently considered an indication for a third dose.